Comments
The function of RBM20 and thereby the mechanism through which RBM20 mutations may cause DCM remains to be elucidated. The functional relevance of the RRM-1, the RS and the U1 zinc-finger domain can be readily deducted from their strict conservation among vertebrates. The RRM-1 domain is thought to bind the target transcript precursor and regulate splicing [4, 7]. Therefore one could speculate that the RBM20 mutation V535I residing in the highly conserved RRM-1 region may interfere with its RNA-binding capacity.
Four RBM20 mutations (R634Q, R634C, R636C, and R636H) altered two highly conserved arginine residues in its RS-rich region. Since the RS-rich domain is predicted to be involved in protein–protein interaction [4, 7], those mutations may affect the ability of RBM20 to interact with other spliceosome proteins, thus disrupting the normal RNA splicing process.
A pathogenic link between genetic disruption of alternative splicing-regulating RS proteins of the spliceosome and DCM has been established earlier in mouse models [8, 9].
Furthermore, the general alternative splicing factor/splicing factor 2 (ASF/SF2) has been directly implicated in the transition between fetal and adult gene programs within the heart [9].
Whether RBM20 acts in a similar manner remains to be investigated, but it will be interesting to define the transcripts of which splicing is regulated by RBM20. This information will elucidate the downstream pathways involved in the etiology of DCM and may eventually help to explore possible therapies.
Clinical implications and prospects
The results described in Li et al., confirm that RBM20 mutations should be considered in familial DCM. It further corroborates that RBM20 mutations are frequently associated with a clinically aggressive form of DCM. This includes severe heart failure, arrhythmia, and the need for cardiac transplantation at ages younger than for sporadic DCM, suggesting that this may be an important cause of familial DCM. This independent confirmation after the initial report in 2009 by Brauch et al. [3] more firmly suggests RBM20 as a novel candidate gene to the list of DCM associated genes. However, its precise frequency and pathophysiological role still needs to be determined. Most importantly, close examination of the described families reveals that penetrance may be variable and in the only large pedigree described by Li et al, variations in other DCM related genes were found as well. A robust pathophysiological role for RBM20 in DCM therefore still needs to be established,
Given the suggested malignancy of RBM20 mutations, finding mutations would suggest a closer clinical follow up, careful attention to coexistent modifiable risk factors, and earlier application of therapies proven to inhibit the process of heart failure and decrease the risk of sudden death.